Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
Authors:
Open Access
- 27 January 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 818179
Abstract
Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, such as hypercalcemia, renal failure, anemia, and bone lesions. Despite improvement in the survival of MM patients with use of myeloma-targeted and immunomodulatory therapies, MM remains an incurable disease. Moreover, patients with relapsed or refractory MM show poor survival outcomes. In recent years, there has been a growing interest in the use of traditional Chinese medicinal materials (TCMMs) for management of a wide spectrum of diseases. The bioactive ingredients derived from TCMMs hold great potential for the development of anticancer drugs. Here we summarize the evidence of the pharmacological effects of the active components in TCMMs on MM, including curcumin, resveratrol, baicalein, berberine, bufalin, cinobufagin, gambogic acid, ginsenoside, icariin, daidzin, formononetin, polysaccharides extracts from Hedyotis difus, and scutellarein. Available evidence indicates that the anti-MM effects of these bioactive ingredients are mediated via regulation of proliferation, apoptosis, autophagy, cell cycle, osteogenic differentiation, and drug resistance. In the future, the underlying mechanisms of the anti-MM effects of these components should be further investigated. Large-scale and well-designed clinical trials are also required to validate the efficacy of these bioactive constituents for MM.Keywords
This publication has 88 references indexed in Scilit:
- Targeting Poly (ADP-Ribose) Polymerase Partially Contributes to Bufalin-Induced Cell Death in Multiple Myeloma CellsPLOS ONE, 2013
- Curcumin and neurodegenerative diseasesBioFactors, 2013
- High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell deathProceedings of the National Academy of Sciences, 2012
- Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROSOncology Letters, 2012
- Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogsInternational Journal of Molecular Medicine, 2011
- Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cellsExperimental Hematology, 2011
- Inhibitory effect of baicalein on IL‐6‐mediated signaling cascades in human myeloma cellsEuropean Journal of Haematology, 2010
- A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cellsMolecular Cancer, 2010
- Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice modelMolecular Cancer Therapeutics, 2009
- Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cellsBlood, 2005